BridgeBio (NASDAQ: BBIO) CEO has 71K RSUs vest, withholds shares for taxes
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. (BBIO) reported that its Chief Executive Officer, Neil Kumar, had 71,217 Restricted Stock Units (RSUs) convert into an equal number of shares of common stock on August 16, 2026. Corresponding RSU derivative positions were eliminated as the awards vested and settled into common shares.
To cover associated tax obligations from this vesting, 36,237 shares of common stock were delivered or withheld at a price of $79.86 per share. Following these transactions, indirect holdings reported include 515,686 shares held by the Kumar Haldea Family Irrevocable Trust, 3,568,447 shares held by the Kumar Haldea Revocable Trust, and 750,000 shares held by the NK 2026 GRAT, with the reporting person disclaiming beneficial ownership of these trust-held shares except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 34,980 shares
Net Buy
12 txns
Insider
Kumar Neil
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F6 | 33,544 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F7 | 19,599 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F8 | 11,554 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F9 | 6,520 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 33,544 | -- | -- |
| Exercise | Common Stock F1 | 19,599 | -- | -- |
| Exercise | Common Stock F1 | 11,554 | -- | -- |
| Exercise | Common Stock F1 | 6,520 | -- | -- |
| Tax Withholding | Common Stock F2 | 36,237 | $79.86 | $2.89M |
| holding | Common Stock F3 | -- | -- | -- |
| holding | Common Stock F4, F3 | -- | -- | -- |
| holding | Common Stock F4, F5 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 391,496 shares (Direct);
Common Stock — 278,307 shares (Direct);
Common Stock — 515,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.);
Common Stock — 3,568,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.);
Common Stock — 750,000 shares (Indirect, By NK 2026 GRAT)
Footnotes (9)
- F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- F2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,217 shares of Common Stock underlying the Reporting Person's RSUs.
- F3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- F4. Reflects a prior transfer of 750,000 shares of Common Stock from the Kumar Haldea Revocable Trust to the NK 2026 GRAT. The transfer constituted only a change in form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
- F5. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
- F6. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- F7. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- F8. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- F9. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Key Figures
RSUs vested and converted: 71,217 shares
Shares withheld for taxes: 36,237 shares
Tax withholding price: $79.86 per share
+4 more
7 metrics
RSUs vested and converted
71,217 shares
Common stock underlying RSUs vesting and settlement on August 16, 2026
Shares withheld for taxes
36,237 shares
Common stock delivered/withheld to satisfy tax obligations on RSU vesting
Tax withholding price
$79.86 per share
Price used for shares withheld to satisfy tax obligations
Family Irrevocable Trust holdings
515,686 shares
Indirect common stock held by Kumar Haldea Family Irrevocable Trust
Revocable Trust holdings
3,568,447 shares
Indirect common stock held by Kumar Haldea Revocable Trust
NK 2026 GRAT holdings
750,000 shares
Indirect common stock held by NK 2026 GRAT
RSU vesting fraction
1/16th
Portion of RSU grants vesting initially and quarterly thereafter
Key Terms
Restricted Stock Unit, grantor retained annuity trust, pecuniary interest, beneficial ownership, +1 more
5 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
grantor retained annuity trust financial
"These shares are held by the NK 2026 GRAT, a grantor retained annuity trust"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
pecuniary interest financial
"disclaims beneficial ownership of these shares except to the extent of his pecuniary interest"
beneficial ownership financial
"this report shall not be deemed to be an admission that such shares are beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Rule 16a-13 regulatory
"exempt under Rule 16a-13 of the Securities Exchange Act of 1934"
FAQ
What did BBIO CEO Neil Kumar report in this Form 4 filing?
Neil Kumar reported the vesting and settlement of 71,217 RSUs into common stock of BridgeBio Pharma, Inc., along with a tax-withholding share disposition and updated indirect shareholdings held through various trusts associated with him.
How many BridgeBio (BBIO) RSUs vested and converted to common stock?
A total of 71,217 RSUs vested and converted into an equal number of BridgeBio common shares. These came from several RSU grants that vest in 1/16th increments starting in May of 2023, 2024, 2025, and 2026, subject to continued service.
What is the vesting schedule of Neil Kumar’s RSUs at BridgeBio (BBIO)?
For each RSU grant, 1/16th of the underlying shares vested on May 16 of the initial year (2023, 2024, 2025, or 2026), and 1/16th vests quarterly thereafter, subject to his continued service; the RSUs have no expiration date.
Were Neil Kumar’s reported BridgeBio (BBIO) transactions under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes describe vesting, tax withholding, and trust structures, without stating that these transactions were executed under a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
